Carisma Therapeutics Reports First Quarter 2023 Financial Re

/PRNewswire/ -- Carisma Therapeutics Inc. (Nasdaq: CARM) ("Carisma" or the "Company"), a clinical-stage biopharmaceutical company focused on discovering and...

Related Keywords

Texas , United States , Philadelphia , Pennsylvania , University Of Pennsylvania , Oregon , American , Steven Kelly , Lin Guey , Jeanetted Hsu , Padmanee Sharma , Sarah Cannon Cancer Research Institute , University Of Texas Md Anderson Cancer Center , Nasdaq , Company Phase , Drug Administration , Company Current Report On Form , Ctx Operations Inc , Sesen Bio Inc , Exchange Commission , University Of Pennsylvania Abramson Cancer Center , Md Anderson Cancer Center , Therapeutics Inc , American Association For Cancer Research , City Of Hope National Medical Center , Fred Hutchinson Cancer Center , Carisma Therapeutics Inc , Novartis , Oregon Health Science University , Prnewswire Carisma Therapeutics Inc , Research Ventures , Moderna Inc , Sesen Bio , Chief Executive Officer , American Association , Cancer Research , Annual Meeting , Nasdaq Global Market , Scientific Advisory Board , Genitourinary Medical Oncology , Endowed Chair , Cell Biology , External Research Ventures , Investigational New Drug , Pennsylvania Abramson Cancer Center , Hope National Medical Center , Cancer Center , Oregon Health , Science University , Fred Hutchinson Cancer , Private Securities Litigation Reform Act , Current Report , Annual Report , Quarterly Report , Convertible Preferred Stock , Stockholder Equity , Carisma Therapeutics , Consolidated Statements ,